• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by SCYNEXIS Inc.

    12/11/24 3:57:20 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCYX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0000912577
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Scynexis, Inc.
    SEC File Number
    001-36365
    Address of Issuer
    1 Evertrust Plaza 13th Floor
    Jersey City
    NEW JERSEY
    07302-6548
    Phone
    201-884-5485
    Name of Person for Whose Account the Securities are To Be Sold
    Federated Hermes Kaufmann Fund II, a portfolio of Federated Hermes Insurance Series
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    10% Stockholder

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    JonesTrading International Services LLC
    555 Saint Charles Drive, Suite 200
    Thousand Oaks � CA � 91360
    1098813515.243794899112/11/2024
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Stock04/15/2015Secondary Offering-Open MarketCompany UnknownCheckbox not checked4091404/15/2015Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    12/11/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Stephen Van Meter

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $SCYX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCYX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCYX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

      First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical holdResumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone due in six months; as previously disclosed GSK disputes these milestone payments, and SCYNEXIS vigorously disagrees with their position JERSEY CITY, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that patient dosing has resumed in the Phase 3 MARIO study, which is an innovative study to investigate oral ibrexafungerp as a

      5/28/25 8:30:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Ibrexafungerp clinical hold lifted by the FDA. SCYNEXIS working to resolve a disagreement with GSK involving the restart of the MARIO study. GSK remains committed to the commercialization of Brexafemme.Hansoh recently received Chinese (NMPA) approval for ibrexafungerp in the treatment of acute VVC. SCYNEXIS will receive a milestone payment from Hansoh upon commercialization as well as royalties of approximately 10% on China sales.Presented positive preclinical data for its second-generation fungerp candidate, SCY-247, at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) meeting; Company expects to report initial Phase 1 data for SCY-247 in Q3 2025.    SCYNEXIS end

      5/15/25 4:20:00 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

      JERSEY CITY, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Vienna, Austria being held from April 11-15, 2025. SCY-247 is being developed to address systemic fungal diseases, with a key focus on invasive fungal infections where resistance to current limited treatment options is a significant concern. These presentations at ESCMID Global

      4/8/25 8:00:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

      Submission status for SCYNEXIS, INC's drug BREXAFEMME (ORIG-1) with active ingredient IBREXAFUNGERP has changed to 'Approval' on 06/01/2021. Application Category: NDA, Application Number: 214900, Application Classification: Type 1 - New Molecular Entity

      6/2/21 11:20:46 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

      Submission status for SCYNEXIS, INC's drug BREXAFEMME (SUPPL-1) with active ingredient IBREXAFUNGERP has changed to 'Approval' on 06/01/2021. Application Category: NDA, Application Number: 214900, Application Classification: Type 1 - New Molecular Entity

      6/2/21 9:57:42 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Angulo Gonzalez David was granted 23,000 shares, increasing direct ownership by 3% to 816,598 units (SEC Form 4)

      4 - SCYNEXIS INC (0001178253) (Issuer)

      4/10/25 8:02:09 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Angulo Gonzalez David was granted 18,800 shares, increasing direct ownership by 2% to 793,598 units (SEC Form 4)

      4 - SCYNEXIS INC (0001178253) (Issuer)

      3/20/25 7:39:22 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Sukenick Scott was granted 92,511 shares, increasing direct ownership by 27% to 436,706 units (SEC Form 4)

      4 - SCYNEXIS INC (0001178253) (Issuer)

      1/27/25 4:05:22 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Angulo Gonzalez David bought $27,400 worth of shares (20,000 units at $1.37), increasing direct ownership by 4% to 507,871 units (SEC Form 4)

      4 - SCYNEXIS INC (0001178253) (Issuer)

      9/16/24 8:00:27 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aegis Capital reiterated coverage on SCYNEXIS with a new price target

      Aegis Capital reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $35.00 from $40.00 previously

      6/7/21 9:58:05 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aegis Capital reiterated coverage on SCYNEXIS with a new price target

      Aegis Capital reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $40.00 from $45.00 previously

      4/12/21 12:54:40 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group reiterated coverage on SCYNEXIS with a new price target

      Maxim Group reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $22.00 from $17.00 previously

      2/17/21 2:23:39 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    SEC Filings

    See more
    • SEC Form 10-Q filed by SCYNEXIS Inc.

      10-Q - SCYNEXIS INC (0001178253) (Filer)

      5/15/25 4:01:36 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by SCYNEXIS Inc.

      DEFA14A - SCYNEXIS INC (0001178253) (Filer)

      4/30/25 4:03:33 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by SCYNEXIS Inc.

      DEF 14A - SCYNEXIS INC (0001178253) (Filer)

      4/30/25 4:01:58 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    Leadership Updates

    Live Leadership Updates

    See more
    • AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti

      Lyon - France, July 24, 2023 (GLOBE NEWSWIRE) -- AUROBAC THERAPEUTICS WELCOMES TWO NEW INDEPENDENT MEMBERS TO ITS BOARD: MANOS PERROS, AS CHAIRMAN, AND MARCO TAGLIETTI Dr Manos Perros and Dr Marco Taglietti are appointed new Independent Members of the Board of AUROBAC THERAPEUTICSDr Perros becomes Chairman of the Board These new appointments bring extensive US and international experience in company leadership and development of anti-infectives from R&D to commercialization Lyon (France), Thursday July 24, 2023 AUROBAC THERAPEUTICS SAS, a biopharmaceutical company developing the next generation of products to fight antimicrobial resistance (AMR), is delighted to announce th

      7/24/23 8:00:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update

      Secured non-dilutive funding of approximately $35 million thus far in 2021, including licensing payments from Hansoh Pharma, the first tranche from a term loan agreement with Hercules and Silicon Valley Bank, and the monetization of the 2020 New Jersey NOLsAppointed Christine Coyne as Chief Commercial Officer to lead the launch of ibrexafungerp (Brexafemme®) for the treatment of vaginal yeast infections, following expected approval by June 1st Began dosing patients in a Phase 1 trial of the IV formulation of ibrexafungerpFurther strengthened balance sheet and projected cash runway into 2023 JERSEY CITY, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology c

      5/17/21 8:30:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® Launch

      Strengthening the management team with deep anti-infective commercial expertise across hospital and community settings ahead of anticipated approval of Brexafemme (ibrexafungerp) in June 2021 and H2:2021 launch JERSEY CITY, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the appointment of Christine Coyne as Chief Commercial Officer, effective May 10, 2021. Ms. Coyne will play a significant role in the anticipated U.S. launch and commercialization of Brexafemme, the expected trade name for ibrexafungerp, an oral antifungal p

      5/11/21 8:30:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    Financials

    Live finance-specific insights

    See more
    • GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection

      Brexafemme complements GSK's industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royaltiesSCYNEXIS retains rights to all other assets derived from enfumafungin, with GSK having a right of first negotiation to these pre-clinical and discovery stage assetsSCYNEXIS to host an investor call and webcast at 8:30 a.m. EDT today LONDON and JERSEY CITY, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- GSK plc (NYSE:GSK) and SCYNEXIS, Inc. (NASDAQ:SCYX), today announced they have entered into an exclusive licence agreement for Brexafemme (i

      3/30/23 7:05:00 AM ET
      $GSK
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      SCYNEXIS recently announced new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications.Ivor Macleod, a 30-year biopharma veteran, joined SCYNEXIS as Chief Financial Officer.Marco Taglietti, M.D., to retire as President and Chief Executive Officer of SCYNEXIS and step down from the Board of Directors on December 31, 2022. David Angulo, M.D., Chief Medical Officer of SCYNEXIS will become President and Chief Executive Officer and join the Board effective January 1, 2023.BREXAFEMME® (ibrexafungerp tablets) prescriptions continued to grow in Q3 2022, increasing 13% over Q2 2022, generating net revenues of $1.6 million in Q3

      11/9/22 7:00:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9

      JERSEY CITY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. EDT on Wednesday, November 9, 2022, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2022. Conference call and webcast details: Investors (domestic): (844) 826-3033Investors (international): (412) 317-5185Webcast:  LinkConference ID: 10172836 A live audio webcast can be accessed by visiting the Investor Relations section of the Company'

      11/1/22 8:30:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

      SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

      11/14/24 7:07:26 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

      SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

      11/6/24 8:56:32 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

      SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

      10/7/24 1:38:20 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care